Trial Profile
A phase II trial to evaluate naloxone in patients with eating disorders
Status:
Planning
Phase of Trial:
Phase II
Latest Information Update: 16 Jun 2016
Price :
$35
*
At a glance
- Drugs Naloxone (Primary)
- Indications Eating disorders
- Focus Therapeutic Use
- 16 Jun 2016 New trial record
- 09 Jun 2016 According to an Opiant Pharmaceuticals media release, the company plans to initiate dosing in this trial in Q1 2017.